|Bid||20.81 x 1000|
|Ask||20.86 x 1800|
|Day's Range||20.58 - 21.52|
|52 Week Range||20.58 - 56.70|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.83|
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the.
If you own shares in Portola Pharmaceuticals Inc (NASDAQ:PTLA) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Portola Pharmaceuticals, Inc.® (PTLA) today announced its 2018 partnership with the World Thrombosis Day campaign to help raise global awareness of thrombosis. Observed annually on October 13, World Thrombosis Day is led by the International Society on Thrombosis and Haemostasis (ISTH), which has mobilized more than 1,500 partner organizations worldwide this year to shine a spotlight on the burden of arterial or venous thrombosis – the potentially life-threatening formation of blood clots in an artery or vein – and conditions caused by it.
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.
Portola Pharmaceuticals (PTLA) is focused on the development and commercialization of novel therapies with a special focus on thrombosis and hematologic diseases. Portola Pharmaceuticals currently has two FDA-approved drugs, Andexxa and Bevyxxa. Portola Pharmaceuticals is advancing its investigational drug, cerdulatinib, which is a Syk/JAK inhibitor.
Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.
Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF). It’s currently approved for three indications. Xarelto was approved in Europe in 2008 and the United States in 2011. It’s sold in the United States by JNJ’s Janssen and outside the United States by Bayer, which has the commercialization rights for Xarelto.
Portola Pharmaceuticals (PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to cerdulatinib, an investigational, oral Syk/JAK inhibitor for the treatment of peripheral T-cell lymphoma (PTCL). “We are pleased that the FDA has granted cerdulatinib Orphan Drug Designation, as it recognizes its potential to provide a significant clinical benefit to a group of patients with limited treatment options,” said John Curnutte, M.D., Ph.D., Portola’s interim co-president and head of research and development.
Portola Pharmaceuticals, Inc.® (PTLA) today announced the appointment of industry veteran Scott Garland as president and chief executive officer, effective October 8, 2018. Mr. Garland brings to his new role more than two decades of broad executive leadership experience, including a strong track record driving multiple billion dollar product launches. Mr. Garland joins Portola from Relypsa, Inc., where he was president and previously chief commercial officer. During his tenure, Mr. Garland was responsible for the integration and growth of the U.S. operations after Relypsa was acquired by Vifor Pharma Group in 2016.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Genomic ...
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement (PAS) filing for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. The PAS has been assigned a Prescription Drug User Fee Act (PDUFA) date of December 31, 2018.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September 21, 2018 to pursue opportunities outside the Company. The Company has engaged a leading executive search firm to assist management in identifying and recruiting a new chief commercial officer in parallel with the Company’s search for a chief executive officer. During the transition period, Mardi C. Dier, interim co-president and chief financial officer, will lead the Company’s commercial activities, including the ongoing launches of Andexxa® and Bevyxxa®.
The stock option shall have an exercise price per share of $29.85, the closing price per share of the Company’s Common Stock on August 31, 2018, and will vest over four years, with 25 percent of the shares vesting on August 20, 2019, the one-year anniversary of the vesting commencement date, and the remaining shares vesting ratably over the subsequent 36 months, subject to Mr. Meyer’s continued service with the Company. The stock option has a ten-year term and is subject to the terms and conditions of the Company’s Inducement Plan and the stock option agreement pursuant to which the option was granted.
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Portola Pharmaceuticals, Inc.® (PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA) for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. Based on FDA timelines, the Company expects a final decision on the PAS in Q1 2019.
The Company will conduct one-on-one meetings with institutional investors at this conference. The Company will participate in a fireside chat presentation at the conference, which will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
Jeffrey Bird, a longtime director at Portola Pharmaceuticals, placed a big bet last week that the biotech’s stock would rebound. From Aug. 21 through Aug. 23, Bird bought a total of 390,000 Portola (PTLA) shares for $10 million, or about $25.84 each, according to a filing he made with the Securities and Exchange Commission. Bird and Portola didn’t respond to calls seeking comment on the stock purchases.
Portola Pharmaceuticals (PTLA) reported net revenues of $4.0 million in the second quarter. PTLA posted net revenues of $3.8 million in the second quarter of 2017, reflecting ~6.0% YoY (year-over-year) growth. In the first half, Portola Pharmaceuticals reported net revenues of $10.7 million, compared to $8.9 billion in the first half of 2017.
Portola Pharmaceuticals (PTLA) stock closed at $28.74 on August 27, which represents ~2.02% growth from its close of $28.17 on August 24. On August 24, Portola Pharmaceuticals stock witnessed ~9.06% growth to reach $28.17 from its August 23 close of $25.83.
Portola Pharmaceuticals Inc (NASDAQ: PTLA ), a biotech focusing on thrombosis, other hematological disorders and inflammation, received a one-notch upgrade from Credit Suisse. The Analyst Analyst Vamil ...